Edgewise Therapeutics, Inc.
EWTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 2.41 | -0.28 | -0.15 | -0.12 |
| FCF Yield | -4.47% | -14.01% | -12.14% | -4.52% |
| EV / EBITDA | -18.48 | -5.46 | -6.88 | -17.25 |
| Quality | ||||
| ROIC | -34.16% | -35.16% | -6.19% | -15.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.81 | 0.92 | 0.78 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -12.95% | -67.91% | -70.24% | -130.34% |
| Safety | ||||
| Net Debt / EBITDA | 0.28 | 0.72 | 0.26 | 0.36 |
| Interest Coverage | 0.00 | 0.00 | -5.50 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -889.23 | -848.22 | -4,141.87 | -5,156.97 |